Bernard, A.; Danigo, A.; Mroué, M.; Rovini, A.; Richard, L.; Nizou, A.; Desmoulière, A.; Sturtz, F.; Demiot, C.; Bourthoumieu, S.
Blockade of Cholecystokinin Type 2 Receptors Prevents the Onset of Vincristine-Induced Neuropathy in Mice. Pharmaceutics 2022, 14, 2823.
https://doi.org/10.3390/pharmaceutics14122823
AMA Style
Bernard A, Danigo A, Mroué M, Rovini A, Richard L, Nizou A, Desmoulière A, Sturtz F, Demiot C, Bourthoumieu S.
Blockade of Cholecystokinin Type 2 Receptors Prevents the Onset of Vincristine-Induced Neuropathy in Mice. Pharmaceutics. 2022; 14(12):2823.
https://doi.org/10.3390/pharmaceutics14122823
Chicago/Turabian Style
Bernard, Amandine, Aurore Danigo, Mohamad Mroué, Amandine Rovini, Laurence Richard, Angélique Nizou, Alexis Desmoulière, Franck Sturtz, Claire Demiot, and Sylvie Bourthoumieu.
2022. "Blockade of Cholecystokinin Type 2 Receptors Prevents the Onset of Vincristine-Induced Neuropathy in Mice" Pharmaceutics 14, no. 12: 2823.
https://doi.org/10.3390/pharmaceutics14122823
APA Style
Bernard, A., Danigo, A., Mroué, M., Rovini, A., Richard, L., Nizou, A., Desmoulière, A., Sturtz, F., Demiot, C., & Bourthoumieu, S.
(2022). Blockade of Cholecystokinin Type 2 Receptors Prevents the Onset of Vincristine-Induced Neuropathy in Mice. Pharmaceutics, 14(12), 2823.
https://doi.org/10.3390/pharmaceutics14122823